First-in-Class Cancer Therapies. Transforming Tomorrow's Care Today.

Innovative targeted therapies for a new era in cancer care.

Ymmunobio Achieves Major Preclinical Milestone with YB-800 ADCs

“We believe in a future where cancer no longer has the final say. Our vision is a new generation of therapies that are not only targeted and effective, but also give hope. Precise, individualized, scientifically sound, so that every patient has real prospects for the future.”

Advancing Targeted Therapies for Solid Tumors

Ymmunobio is advancing a first-in-class program against NPTXR—a tumor-exclusive “beacon” prevalent across 17+ major solid tumors (e.g., colorectal, gastric, squamous NSCLC, breast incl. TNBC, cervix, bladder)—via a staged multi-modal platform (RPT → BiTCE → ADC, with a CAR-T option), with initial human proof-of-concept targeted for 2028.

Dual-payload ADC

(3rd generation linker) ADR=8

Radiopharmaceuticals

(therapy & diagnostic- scanning)

Bispecific T-cell engagers

CAR-T cell therapy

Development Strategy

We aim to reach IND fast and generate early human data. Radiopharmaceuticals and bispecific T-cell engagers lead the way, while the ADC remains the flagship with proof-of-concept in 2028.

Sequencing at a glance:

Antibody Drug Conjugate (ADC)

dual-payload, 3rd-gen linker; clinical PoC by 2028

Radiopharmaceuticals (RPT)

imaging → therapeutic ¹⁷⁷Lu/¹⁶¹TB

Bispecific T-Cell Engagers (BiTCE)

rapid IND, early FIH

Why NPTRX?

High Pan-Tumor Prevalence

NPTXR is expressed in >17 solid tumors at prevalences up to 98% with H-scores reaching 282, enabling pan-tumor development and expanding therapeutic reach.

Uniform Tumor Expression

Strong and consistent expression in tumor cells and absence in normal tissue supports patient treatment with low risk of off-target toxicity.

Matched Diagnostics

Companion diagnostics, including liquid biopsy, PET and SPECT imaging (RPTs), simplify patient screening and improve cost-effectiveness for payers and providers.

Lasting IP Protection

Ymmunobio holds foundational NPTXR antibody rights from Nagoya University plus composition-of-matter and use claims, ensuring patent protection until 2044 with extension options.

Advancing Cancer Treatment Across Four Platforms

Bi-specific T-Cell Engagers

Next-generation bispecific T-cell engagers (BiTCEs) that redirect T cells to NPTXR-positive tumors, driving highly selective immune-mediated killing.

Antibody-Drug-Conjugates

Dual-payload anti-NPTXR ADCs using third-generation 4+4 linker–payload architecture (MMAF + exatecan), engineered for precise tumor targeting and potent cytotoxic delivery.

Antibody-Radionuclide

Two RPTs with ¹⁷⁷Lu/¹⁶¹Tb for NPTXR-targeted Dx/Tx, enabling early PK/engagement readouts and dosimetry to speed ind

CAR-T-Cell Therapy

NPTXR-directed CAR-Ts using validated binders enable tumor-exclusive killing across solid tumors while sparing healthy tissue, retained as a later-stage platform expansion.

3rd place in biotech startup 2024

Our proud partners

Our Leadership Team

Peter Schiemann, PhD

Co-Founder Ymmunobio
CEO & Chairman

Michel Janicot, PhD

Chief Development Officer

Martin Zuzulo

Chief Operating Officer

Christian Germa, MSc

Chief Financial Officer

Selena Blackmore

Director Business Operations

Estelle Chao, MBA

Head of Business Development

With data from radiopharmaceuticals and bispecifics, and a flagship ADC readout expected in 2028, Ymmunobio offers investors both early catalysts and long-term upside.

Get in touch

We want to hear from you. Please use the contact form and follow us on Linkedln to keep with the Ymmunobio news!